Outpatient therapy in metastatic breast cancer. A retrospective study of 90 patients treated in an oncology group practice

Onkologie

Volumn 27, Issue 4, 2004, Pages 380-384

  Weide, R ^a   Grass, J ^a   Heymanns, J ^a   Pandorf, A ^a   Kleboth, K ^a   Koppler H ^a  

^a Praxisklinik F Hamatologie O   (Germany)

Author keywords

Breast cancer; Metastatic; Outpatient treatment

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; HORMONE; TAXANE DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; FEBRILE NEUTROPENIA; FOLLOW UP; HOME; HORMONAL THERAPY; HOSPITALIZATION; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; ONCOLOGY; OUTPATIENT CARE; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GERMANY; GROUP PRACTICE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PALLIATIVE CARE; PATIENT ADMISSION; PATIENT CARE TEAM; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 4644245844     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079092     Document Type: Article

References (19)

1. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland: Krebs in Deutschland. 2. Aktualisierte Ausgabe, Saarbrücken, 1999.
2. Greenberg PAC, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-2205.
3. Möbus V, Kreienberg R: Systemische Therapie des metastasierten Mammakarzinoms; in Kreienberg R, Möbus V, Alt D (Hrsg): Management des Mammakarzinoms. Berlin, Springer, 1998, pp 233-260.
4. Heidemann E: Therapeutic aspects of advanced high risk breast cancer. Onkologie 1990;13:338-344.
5. Rubens RD: Routine management of disseminated disease (including anti-osteoclastic therapy); in Bonadonna G, Hortobagyi GN, Gianni AM (eds): Textbook of Breast Cancer - A Clinical Guide to Therapy. London, Martin Dunitz, 1997, pp 169-180.
6. von Moos R, Thurlimann B: Weekly paclitaxel (Taxol) with or without trastuzumab (Herceptin) in advanced breast cancer: A community-based observation study. Onkologie 2003;26:128-132.
7. Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, Fisher E, Deutsch M, Caplan R, Pilch Y, Glass A, Shibata H, Lerner H, Terz J, Sidorovich L: Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irridiation in the treatment of breast cancer. N Engl J Med 1989;320:822-828.
8. Jacobsen JA, Danforth DN, Cowan KH, D'Angelo T, Steinberg SM, Pierce L, Lippman ME, Lichter AS, Glatstein E, Okunieff P: Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 1995;332:907-911.
9. Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Hohneker J: Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995;13:2722-2730.
10. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B: Multicenter, randomized comparative study of two doses of paclitaxel patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-1867.
11. Romero Acuña L, Langhi M, Pérez J, Romero Acuña J, Machiavelli M, Lacava J, Vallejo C, Romero A, Fasce H, Ortiz E, Grasso S, Amato S, Rodriguez R, Barbieri M, Leone B: Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 1999;17:74-81.
12. Clark GM, Sledge GW Jr., Osborne K, McGuire WL: Survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987;5:55-61.
13. Rahmann ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, Hortobagyi GN: Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. Cancer 1999;85:104-111.
14. Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, Freytes CO, Gale RP, Hillner BE, Holland HK, Kennedy MJ, Klein JP, Lazarus HM, McCarthy PL Jr., Saez R, Spitzer G, Stadtmauer EA, Williams SF, Wolff S, Sobocinski KA, Armitage JO, Horowitz MM: High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997;15:1870-1879.
15. Falkson G, Gelman R, Falkson CI, Glick J, Harris J: Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: A prospective Eastern Cooperative Oncology Group Study. J Clin Oncol 1991;9:2153-2161.
16. Anderson WF, Reeves JE, Elias A, Berkel H: Outcome of patients with metastatic breast carcinoma treated at a private medical oncology clinic. Cancer 2000;88:95-107.
17. Bonneterre J, Mercier M: Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. Cancer Treat Rev 1993;19(Suppl B):21-30.
18. Rubens RD, Bajetta E, Bonneterre J, Klijn JGM, Lønning PE, Paridaens R: Treatment of relapse of breast cancer after adjuvant systemic therapy - review and guidelines for future research. Eur J Cancer 1994;30A:106-111.
19. Huang J, Boyd C, Tyldesley S, Zhang-Salomons J, Groome PA, Mackillop WJ: Time spent in hospital in the last six months of life in patients who died of cancer in Ontario. J Clin Oncol 2002;20:1584-1592.